Federal Register / Vol. 62, No. 55 / Friday, March 21, 1997 / Notices 13659

health 17.1 percent; allied health 18.2

percent; and clinical psychology 18

percent.

Nonstatutory Special Consideration for

Baccalaureate Nursing Programs

Among schools of nursing, additional

special consideration will be given to

baccalaureate programs. One of the

distinguishing features of baccalaureate

education is the substantial focus on

preparation for community health

practice. Training nurses for community

health practice is an integral component

of the Department’s access strategy.

It is not required that new applicants

request consideration for a funding

factor. Applications from new schools

which do not request consideration for

funding factors will be reviewed and

given full consideration for funding.

Procedures for Calculating Awards

Awards to eligible schools will be

calculated by comparing the enrollment

of disadvantaged students in each

eligible school with the total enrollment

of the disadvantaged students in all

eligible schools.

A school with an enrollment of

underrepresented minority students

which is above the national average (for

each discipline) will be given double

credit (i.e., its enrollment of

disadvantaged students would be

doubled for awarding purposes). A

baccalaureate nursing school will be

given double credit. A baccalaureate

nursing school with an

underrepresented minority enrollment

above the national average will be given

quadruple credit (i.e., its enrollment of

disadvantaged students will be

multiplied by four for awarding

purposes).

Other Consideration

Other funding factors may be applied

in determining the funding of eligible

schools.

A funding preference is defined as the

funding of a specific category or group

of eligible schools ahead of other

categories or groups of eligible schools.

A funding priority is defined as the

favorable adjustment of aggregate review

scores of individual approved

applications when applications meet

specified criteria.

It is not required that new applicants

request consideration for a funding

factor. Applications from new schools

which do not request consideration for

funding factors will be reviewed and

given full consideration for funding.

Funding Preference and Priority

For fiscal year 1997, among allied

health schools or programs, preference

will be given to the following

baccalaureate and graduate programs:

dental hygiene, medical laboratory

technology, occupational therapy,

physical therapy and radiologic

technology. In addition, priority among

allied health applicants will be given to

dental hygiene. A priority for dental

hygiene will be implemented by taking

the total funds allocated to the allied

health disciplines in the initial

allocation and recalculating this part of

the allocation. Dental hygiene schools

will receive double credit for their

disadvantaged enrollments in the

reallocation of the allied health funds.

National Health Objectives for the Year

2000

The Public Health Service is

committed to achieving the health

promotion and disease prevention

objectives of Healthy People 2000, a

PHS-led national activity for setting

priority areas. The Scholarships for

Disadvantaged Students program is

related to the priority area of Academic

and Community Partnership Programs.

Potential applicants may obtain a copy

of Healthy People 2000 (Full Report;

Stock No. 017–001–00474–0) or Healthy

People 2000 (Summary Report; Stock

No. 017–001–00473–1) through the

Superintendent of Documents,

Government Printing Office,

Washington, D.C. 20402–9325

(Telephone (202) 783–3238).

Smoke-Free Workplace

The Public Health Service strongly

encourages all award recipients to

provide a smoke-free workplace and

promote the non-use of all tobacco

products, and Public Law 103–227, the

Pro-Children Act of 1994, prohibits

smoking in certain facilities that receive

Federal funds in which education,

library, day care, health care, and early

childhood development services are

provided to children.

Application Requests

Applications are not required from

schools of medicine, osteopathic

medicine, dentistry, pharmacy,

optometry, podiatric medicine,

veterinary medicine, nursing, public

health, clinical psychology and allied

health which received SDS awards in

FY 1996. Upon request, materials will

be mailed to schools in the disciplines

identified above which did not

participate in the SDS program in FY

1996.

Requests for materials and questions

regarding business management and

program policy should be directed to:

Office for Campus Based Programs,

Division of Student Assistance, Bureau

of Health Professions, Health Resources

and Services Administration, Parklawn

Building, Room 8–34, 5600 Fishers

Lane, Rockville, Maryland 20857.

Telephone: (301) 443–4776; FAX: (301)

443–0846.

The deadline date for submitting

materials from new schools is April 21,

1997. Applications shall be considered

as meeting the deadline if they are

either:

(1) Received on or before the

established deadline date, or

(2) Sent on or before the established

deadline and received in time for

orderly processing. (Applicants should

request a legibly dated U.S. Postal

Service postmark or obtain a legibly

dated receipt from a commercial carrier

or the U.S. Postal Service. Private

metered postmarks shall not be

acceptable as proof of timely mailing.)

Late applications not accepted for

processing will be returned to the

applicant.

The materials for this program (SF

269) have been approved by the Office

of Management and Budget (OMB)

under the Paperwork Reduction Act.

The OMB clearance number is 0348–

0039. In addition, applicants are

required to provide certification that

there is at least one minority faculty

member on staff at the applicant

institution.

The Catalog of Federal Domestic

Assistance Number for the Scholarships for

Disadvantaged Students program is 93.925.

This program is not subject to the provisions

of Executive Order 12372, Intergovernmental

Review of Federal Programs (as implemented

through 45 CFR part 100).

This program is not subject to the

Public Health System Reporting

Requirements.

Dated: March 13, 1997.

Ciro V. Sumaya,

Administrator.

[FR Doc. 97–7140 Filed 3–20–97; 8:45 am]

BILLING CODE 4160–15–P

Public Health Service

Notice Regarding Section 602 of the

Veterans Health Care Act of 1992—

Withdrawal of Rebate Mechanism

AGENCY: Health Resources and Services

Administration (HRSA), Department of

Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: Section 602 of Public Law

102–585, the ‘‘Veterans Health Care Act

of 1992,’’ enacted section 340B of the

Public Health Service Act, ‘‘Limitation

on Prices of Drugs Purchased by

Covered Entities.’’ Section 340B
13660 Federal Register / Vol. 62, No. 55 / Friday, March 21, 1997 / Notices

provides that a manufacturer who sells

covered outpatient drugs to eligible

(covered) entities must sign a

pharmaceutical pricing agreement with

the Secretary of HHS in which the

manufacturer agrees to charge a price for

covered outpatient drugs that will not

exceed that amount determined under a

statutory formula.

The purpose of this notice is to

withdraw the Federal Register notice

entitled, ‘‘Notice Regarding Section 602

of the Veterans Health Care Act of

l992—Rebate Mechanism,’’ published

on March 14, l997. This notice

requested comments on the proposal of

a rebate process for State AIDS Drug

Assistance Programs receiving funds

under Title XXVI of the PHS Act.

FOR FURTHER INFORMATION CONTACT:

Annette Byrne, R. Ph., Director, Office

of Drug Pricing, Bureau of Primary

Health Care, Health Resources and

Services Administration, 4350 East West

Highway, 10th Floor, Bethesda, MD

20814, Phone (301) 594–4353, Fax (301)

594–4982.

SUPPLEMENTARY INFORMATION: HRSA

guidance for the section 340B drug

program has described only a discount

process for accessing 340B pricing.

Although this discount system is

functioning successfully for most

covered entities, some State AIDS Drug

Assistance Programs (ADAPs) have drug

purchasing systems that have prevented

their participation in the 340B drug

program. The use of a rebate mechanism

(in addition to the discount mechanism)

should allow these groups to access

340B pricing.

Because the rebate mechanism is only

a part of a larger endeavor by HRSA to

develop the 340B drug program in such

a manner as to effectively reach all

covered entities, the notice outlining the

concept of a narrowly-focused rebate

mechanism is withdrawn for further

internal deliberation.

Dated: March 14, 1997.

Ciro V. Sumaya,

Administrator.

[FR Doc. 97–7142 Filed 3–20–97; 8:45 am]

BILLING CODE 4160–15–P

National Institutes of Health

Amended Notice of Meeting

Notice is hereby given of a change in

the meeting of the Advisory Committee

on Blood Safety and Availability,

Department of Health and Human

Services, March 20–21, 1997, which was

published in the Federal Register on

March 3, 1997 (62 FR 9441).

This meeting will be held on April

24–25, 1997, instead of the previously

stated March 20–21. The Advisory

meeting remains at the same time and

place, 8:30 a.m., National Institutes of

Health, Warren G. Magnuson Clinical

Center, Jack Masur Auditorium, 9000

Rockville Pike, Bethesda, Maryland

20892. As previously stated, this

meeting will be entirely open to the

public.

On April 24, the Committee will

discuss hepatitis C virus (HCV)

infection, its occurrence following blood

transfusion, other epidemiology of HCV

infection and appropriate ways of

approaching the public health aspects of

this infection. On April 25, the

Committee will address multiple

aspects of the theoretical possibility that

Creutzfeldt-Jakob disease (CJD) can be

transmitted by blood transfusion. For

each topic, a time will be set aside for

the public to comment. Prospective

speakers should notify the Executive

Secretary for this meeting of their wish

to present and should plan for no more

than 5 minutes of comments.

CONTACT: Paul R. McCurdy, M.D.,

Acting Executive Secretary, Advisory

Committee on Blood Safety and

Availability, Director, Blood Resources

Program, DBDR–MSC–7950, NHLBI,

NIH, Bethesda, Maryland 20892–7950.

Phone: 301/435–0065; Fax 301/480–

1060; E-Mail: paullmccurdy@nih.gov.

Dated: March 17, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–7129 Filed 3–20–97; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood

Institutes; Notice of Meeting

Pursuant to Pub. L. 92–463, notice is

hereby given of the meeting of the

following National Heart, Lung, and

Blood Institutes Special Emphasis

Panel.

The meeting will be open to the

public to provide concept review of

proposed contract or grant solicitations.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

inform the Contract Person listed below

in advance of the meeting.

Name of Panel: Stem Cell Transplantation

in Sickle Cell Disease.

Dates of Meeting: April 30, 1997.

Time of Meeting: 10:00 a.m.

Place of Meeting: Two Rockledge Center,

Rm. 9112, 6701 Rockledge Drive, Bethesda,

Maryland 20892.

Agenda: To review current progress and

identify future initiatives in the use of stem

cell transplantation for the treatment of sickle

cell disease.

Contact Person: Helena Mishoe, Ph.D.,

NHLBI/DBDR, Two Rockledge Center, 6701

Rockledge Drive, Rm. 10156, MSC 7950,

Bethesda, Maryland 20892, (301) 435–0050.

(Catalog of Federal Domestic Assistance

Programs Nos. 93.837, Heart and Vascular

Diseases Research; 93.838, Lung Diseases

Research; and 93.839, Blood Diseases and

Resources Research, National Institutes of

Health.)

Dated: March 17, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–7128 Filed 3–20–97; 8:45 am]

BILLING CODE 4140–01–M

Prospective Grant of Exclusive

License: Replicating Tumoricidal Viral

Therapy for Cancer Applications

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i) that the National Institutes

of Health (NIH), Department of Health

and Human Services, is contemplating

the grant of a limited field of use

exclusive license worldwide to practice

the invention embodied in U.S. Patent

Application Number 07/725,076 (issued

on October 25, 1994 as U.S. Patent No.

5,358,866) entitled ‘‘Cytosine

Deaminase Negative Selection System

for Gene Transfer Techniques and

Therapies’’ and its divisional

applications 08/271,874, 08/447,580,

08/447,393, 08/445,203, 08/447,487, 08/

449,627, 08/448,867, 08/449,636, and all

related foreign filings, to ONYX, Inc.,

having a place of business in Richmond,

CA (USA). The patent rights in these

inventions have been assigned to the

United States of America.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 60 days from the date of this

published Notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7. This

notice modifies a previous notice of

April 11, 1996 found in Volume 61,

Number 71 of the Federal Register.

The field of use would be limited to

Replicating Tumoricidal Viral Therapy

for Cancer applications.

The present inventions relate to a

modified bacterial gene for cytosine

deaminase. Specifically, the CD gene

can be used as a negative selectable